| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| palivizumab | complement c1q subcomponent subunit a | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | complement c1q subcomponent subunit b | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | complement c1q subcomponent subunit c | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | complement c1r subcomponent | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | high affinity immunoglobulin gamma fc receptor i | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | low affinity immunoglobulin gamma fc region receptor ii-b | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | low affinity immunoglobulin gamma fc region receptor iii-a | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| palivizumab | low affinity immunoglobulin gamma fc region receptor iii-b | biotech | NA | drugbank | Respiration Disorders[MeSHID:D012120] Respiratory Syncytial Virus Infections[MeSHID:D018357] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | unknown |
| click here to return to the previous page | ||||||||